GP2 is a product and a source of collaboration. The individuals and groups that contribute to GP2 drive its strategy, its operations, and ultimately its impact. Read more.
At GP2, we are committed to creating a global research community with the tools and infrastructure to address emerging research needs and questions. Read more.
GP2 develops and maintains tools that assemble clinical and genetic data to help accelerate research across the Parkinson’s Disease Research community. Read more.
West Kazakhstan Marat Ospanov State Medical University
Aktobe, Kazakhstan
Area of Focus
Biomarker
alpha-synuclein
Central Asia
Clinical Neuroscience
Education
Biography
Assistant of Neurology department
Outputs and publications by Aigerim Utegenova, PhD
Workflows of Data and Samples
The following document outlines the workflow of the data and samples from contributing cohorts with existing DNA, and contributing cohorts with existing or externally generated genotype data.
NIA-Material Transfer Agreement
The material transfer agreement for the transfer of human materials for research purposes is outlined in the following document.
Sample Prioritization Table
The Monogenic Network of GP2 is prioritizing cases where a monogenic cause of Parkinson’s disease is strongly suspected. Multiple factors will be considered and scoring criteria will be used.
